A Study of Olanzapine in Participants With Bipolar Disorder.

Sponsor
Boryung Pharmaceutical Co., Ltd
Study ID
NCT07263191
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Olanzapine — DRUG
    As this is a non-interventional study designed to collect data as part of routine clinical practice, the selection and dosage of medication, treatment period, and whether or not to change it are all based on the clinician's judgment.

Study Details

This study aimed to identify treatment patterns in patients with bipolar disorder receiving olanzapine according to demographic and clinical characteristics and to evaluate the effectiveness of education on weight gain, a side effect of olanzapine, in preventing weight gain.

Key Dates

First listed
Dec 4, 2025
Start date
Oct 30, 2025
Status verified
Nov 2025
Primary completion
Sep 30, 2027
Completion
Sep 30, 2027

Study Design

Enrollment
3,000 participants (estimated)

Primary Outcome Measure

Treatment pattern [ Time Frame: Baseline, 8weeks, 12weeks ]

Central Contacts

Find similar trials

Nationwide
Bipolar disorder trialsPsychiatry trialsMental health trialsBehavioral health trials

Related Studies